Apitegromab

The transcript discusses Apitegromab, a drug recently approved by the FDA for a rare muscle disease (not obesity). In a small 24-week trial involving patients on tirzepatide, adding apitegromab reduced lean muscle loss by more than half compared to those not taking it. The speaker notes that while the data is real, the drug was administered via monthly IV infusions in the study.

The speaker warns that apitegromab is not approved for obesity, and no insurance covers the combination of this drug with GLP-1 agonists like tirzepatide. Chasing access to this medication outside its approved indications is described as a 'complete dead end,' and the speaker explicitly advises against attempting to obtain it currently.

The speaker warns that apitegromab is not approved for obesity and no insurance covers the combination with GLP-1s. Attempting to source or use it currently is described as a 'complete dead end' and is not recommended by the speaker.